Predictive value of TG/HDL-C and GFR-adjusted uric acid levels on cardiovascular mortality: the URRAH study
- PMID: 39856749
- PMCID: PMC11760098
- DOI: 10.1186/s12944-025-02440-w
Predictive value of TG/HDL-C and GFR-adjusted uric acid levels on cardiovascular mortality: the URRAH study
Abstract
Background: Insulin resistance (IR) and serum uric acid (SUA) are closely interconnected: SUA contributes to adversely affects the insulin signaling pathway and contributes to IR, while IR is a known predictor for the development of hyperuricemia. The triglyceride (TG) to high-density lipoprotein cholesterol (HDL-C) ratio has been proposed as an easily obtainable marker for IR. This research aimed to investigate the interaction between IR and glomerular filtration rate (GFR)-adjusted uricemia (SUA/GFR ratio) in determining CV risk in a large population cohort study.
Methods: Data from 18,694 subjects were analyzed from Uric acid Right foR heArt Healt (URRAH) database. The study evaluated the association between TG/HDL-C ratio and SUA/GFR ratio, as well as their impact on the development of outcomes during the follow-up study period. The primary endpoint was CV mortality.
Results: After a mean follow-up of 124 ± 64 months, 2,665 (14.2%) CV deaths occurred. The incidence of fatal and non-fatal CV events increased in parallel with the increase of TG/HDL-C quintiles. TG/HDL-C ratio showed a positive association with increasing of SUA/GFR ratio, even in non-diabetic patients. Multivariate analysis showed that the TG/HDL-C ratio increases the mortality risk even after adjustment for potential confounding factors. Finally, IR and GFR-adjusted hyperuricemia showed an additive effect on CV mortality.
Conclusions: Both IR and SUA/GFR ratio independently predict CV mortality, regardless of age, gender, BMI, diabetes, hypertension and statin use. The joint effect of the TG/HDL-C ratio and the elevated SUA/GFR ratio was greater than the presence of each single risk factor on CV mortality. This highlights the importance of monitoring these markers to better assess cardiovascular risk.
Keywords: Cardiovascular mortality; Insulin-resistance; Kidney function; TG/HDL-C ratio; Triglycerides; Uric acid.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Ethics approval and consent to participate: The URRAH project was performed according to the Declaration of Helsinki for Human Research (41stWorld Medical Assembly, 1990). The processing of the patients’ personal data collected in this study complies with the European Directive on the Privacy of Data. Approval was sought from the Ethical Committee of the coordinating center at the Division of Internal Medicine of the University of Bologna (No. 77/2018/Oss/AOUBo). Informed consent was obtained from all subjects at recruitment. Competing interests: The authors declare no competing interests.
Figures
References
-
- Copur S, Demiray A, Kanbay M. Uric acid in metabolic syndrome: does uric acid have a definitive role? Eur J Intern Med. 2022;103:4–12. 10.1016/j.ejim.2022.04.022. - PubMed
-
- Saito Y, Tanaka A, Node K, Kobayashi Y. Uric acid and cardiovascular disease: a clinical review. J Cardiol. 2021;78(1):51–7. 10.1016/j.jjcc.2020.12.013. - PubMed
-
- Ambrosio G, Leiro MGC, Lund LH, Coiro S, Cardona A, Filippatos G, Ferrari R, Piepoli MF, Coats AJS, Anker SD, Laroche C, Almenar-Bonet L, Poder P, Valero DB, Frisinghelli A, Maggioni AP. Serum uric acid and outcomes in patients with chronic heart failure through the whole spectrum of ejection fraction phenotypes: analysis of the ESC-EORP Heart Failure Long-Term (HF LT) registry. Eur J Intern Med. 2021;89:65–75. 10.1016/j.ejim.2021.04.001. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
